* hypersensitivity to any component of bcg-10 * hypersensitivity to previously administered tuberculin (local skin lesions, necrosis of the skin, blisters, other severe skin reactions at the injection site) * hiv infection (confirmed or suspected infections, even if they are asymptomatic) * primary or secondary immunodeficiencies (including interferon - gamma deficiency or digeorge syndrome) * radiotherapy (less than 24 months before the date of inclusion in the trial * treatment with corticosteroids, ongoing immunosuppressive therapy (including those treated with monoclonal antibodies to tnf-α, such as infliximab) - less than 24 months before the date of inclusion in the trial * neoplastic diseases (e.g. leukaemia, malignant granuloma, lymphoma or some other cancer of the reticuloendothelial system) - less than 24 months before the date of inclusion in the study * after stem cell transplantation and organ transplantation * in the exacerbation stage of chronic diseases (including severe malnutrition) * pregnancy * history of tuberculosis * keloid at the vaccination site after previous bcg vaccination

* hypersensitivity to any component of bcg-10 * hypersensitivity to previously administered tuberculin (local skin lesions, necrosis of the skin, blisters, other severe skin reactions at the injection site) * hiv infection (confirmed or suspected infections, even if they are asymptomatic) * primary or secondary immunodeficiencies (including interferon - gamma deficiency or digeorge syndrome) * radiotherapy (less than 24 months before the date of inclusion in the trial * treatment with corticosteroids, ongoing immunosuppressive therapy (including those treated with monoclonal antibodies to tnf-α, such as infliximab) - less than 24 months before the date of inclusion in the trial * neoplastic diseases (e.g. leukaemia, malignant granuloma, lymphoma or some other cancer of the reticuloendothelial system) - less than 24 months before the date of inclusion in the study * after stem cell transplantation and organ transplantation * in the exacerbation stage of chronic diseases (including severe malnutrition) * pregnancy * history of tuberculosis * keloid at the vaccination site after previous bcg vaccination

- hypersensitivity to any component of bcg-10 - hypersensitivity to previously administered tuberculin (local skin lesions, necrosis of the skin, blisters, other severe skin reactions at the injection site) - hiv infection (confirmed or suspected infections, even if they are asymptomatic) - primary or secondary immunodeficiencies (including interferon - gamma deficiency or digeorge syndrome) - radiotherapy (less than 24 months before the date of inclusion in the trial - treatment with corticosteroids, ongoing immunosuppressive therapy (including those treated with monoclonal antibodies to tnf-α, such as infliximab) - less than 24 months before the date of inclusion in the trial - neoplastic diseases (e.g. leukaemia, malignant granuloma, lymphoma or some other cancer of the reticuloendothelial system) - less than 24 months before the date of inclusion in the study - after stem cell transplantation and organ transplantation - in the exacerbation stage of chronic diseases (including severe malnutrition) - pregnancy - history of tuberculosis - keloid at the vaccination site after previous bcg vaccination

- hypersensitivity to any component of bcg-10 - hypersensitivity to previously administered tuberculin (local skin lesions, necrosis of the skin, blisters, other severe skin reactions at the injection site) - hiv infection (confirmed or suspected infections, even if they are asymptomatic) - primary or secondary immunodeficiencies (including interferon - gamma deficiency or digeorge syndrome) - radiotherapy (less than 24 months before the date of inclusion in the trial - treatment with corticosteroids, ongoing immunosuppressive therapy (including those treated with monoclonal antibodies to tnf-α, such as infliximab) - less than 24 months before the date of inclusion in the trial - neoplastic diseases (e.g. leukaemia, malignant granuloma, lymphoma or some other cancer of the reticuloendothelial system) - less than 24 months before the date of inclusion in the study - after stem cell transplantation and organ transplantation - in the exacerbation stage of chronic diseases (including severe malnutrition) - pregnancy - history of tuberculosis - keloid at the vaccination site after previous bcg vaccination